David Elsley
Founder bei CARDIOL THERAPEUTICS INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
David G.
Elsley is the founder.
He founded Vasogen, Inc. in 1990 and served as Director until 2009.
He also founded Cardiol Therapeutics, Inc. in 2017 and currently serves as President, Chief Executive Officer & Director.
Mr. Elsley holds an MBA from the University of Western Ontario and Richard Ivey School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.02.2024 | 1 154 500 ( 1,77% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von David Elsley
| Unternehmen | Position | Beginn |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Founder | 19.01.2017 |
Ehemalige bekannte Positionen von David Elsley
| Unternehmen | Position | Ende |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Founder | 23.10.2009 |
Ausbildung von David Elsley
| University of Western Ontario | Masters Business Admin |
| Richard Ivey School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
